Anixa Biosciences is trading 5.38% down at $2.64 after H.C. Wainwright lowered its price target to $6 from $7 while maintaining a Buy rating on September 23, 2026.
- The revision followed the company’s Australian breast-cancer-vaccine patent announcement and reflected projected share-count changes.
- No new company announcement dated September 22–23 was identified; biotechnology stocks were broadly stronger, pointing to a company-specific analyst-action catalyst.